Majrashi, A.;                     Gue, Y.X.;                     Shantsila, A.;                     Williams, S.;                     Lip, G.Y.H.;                     Pettitt, A.R.    
        Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. J. Clin. Med. 2024, 13, 7492.
    https://doi.org/10.3390/jcm13237492
    AMA Style
    
                                Majrashi A,                                 Gue YX,                                 Shantsila A,                                 Williams S,                                 Lip GYH,                                 Pettitt AR.        
                Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of Clinical Medicine. 2024; 13(23):7492.
        https://doi.org/10.3390/jcm13237492
    
    Chicago/Turabian Style
    
                                Majrashi, Abdulrahman,                                 Ying X. Gue,                                 Alena Shantsila,                                 Stella Williams,                                 Gregory Y. H. Lip,                                 and Andrew R. Pettitt.        
                2024. "Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study" Journal of Clinical Medicine 13, no. 23: 7492.
        https://doi.org/10.3390/jcm13237492
    
    APA Style
    
                                Majrashi, A.,                                 Gue, Y. X.,                                 Shantsila, A.,                                 Williams, S.,                                 Lip, G. Y. H.,                                 & Pettitt, A. R.        
        
        (2024). Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of Clinical Medicine, 13(23), 7492.
        https://doi.org/10.3390/jcm13237492